Richards, D. A., Braiteh, F. S., Garcia, A. A., Denlinger, C. S., Conkling, P. R., Edenfield, W. J., … Moyo, V. M. (2014). A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors. In Journal of Clinical Oncology (Vol. 32, pp. 651–651). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.651

Richards, Donald A., Fadi S. Braiteh, A. A. Garcia, Crystal Shereen Denlinger, Paul R. Conkling, William Jeffery Edenfield, Stephen Patrick Anthony, et al. “A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors.” In Journal of Clinical Oncology, 32:651–651. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.651.

Richards DA, Braiteh FS, Garcia AA, Denlinger CS, Conkling PR, Edenfield WJ, et al. A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 651–651.

Richards, Donald A., et al. “A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors.” Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. 651–651. Crossref, doi:10.1200/jco.2014.32.15_suppl.651.

Richards DA, Braiteh FS, Garcia AA, Denlinger CS, Conkling PR, Edenfield WJ, Anthony SP, Hellerstedt BA, Raju RN, Becerra C, Harb WA, Smith DA, McDonagh CF, Kawash K-L, Frye S, Moyo VM. A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 651–651.